NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
- State
- Under way
- Phase
- Phase 3
- People
- 182 planned
- Started
- 20 Nov 2024
- Primary completion
- Oct 2029
- Arms
- Rovadicitinib
- Results
- None posted
- 12 Nov 2024: Trial registered
- 20 Nov 2024: Trial started